236 related articles for article (PubMed ID: 17343426)
1. The Erice Manifesto: for global reform of the safety of medicines in patient care.
Drug Saf; 2007; 30(3):187-90. PubMed ID: 17343426
[TBL] [Abstract][Full Text] [Related]
2. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
3. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
[TBL] [Abstract][Full Text] [Related]
4. Evolving paradigms in pharmacovigilance.
Brewster W; Gibbs T; Lacroix K; Murray A; Tydeman M; Almenoff J
Curr Drug Saf; 2006 May; 1(2):127-34. PubMed ID: 18690923
[TBL] [Abstract][Full Text] [Related]
5. Good pharmacovigilance practices: technology enabled.
Nelson RC; Palsulich B; Gogolak V
Drug Saf; 2002; 25(6):407-14. PubMed ID: 12071777
[TBL] [Abstract][Full Text] [Related]
6. Performance assessment of the Thai National Center for Pharmacovigilance.
Kaewpanukrungsi W; Anantachoti P
Int J Risk Saf Med; 2015; 27(4):225-37. PubMed ID: 26756896
[TBL] [Abstract][Full Text] [Related]
7. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
Santoro A; Genov G; Spooner A; Raine J; Arlett P
Drug Saf; 2017 Oct; 40(10):855-869. PubMed ID: 28735357
[TBL] [Abstract][Full Text] [Related]
8. Monitoring medicines use: the role of the clinical pharmacologist.
Williams D
Br J Clin Pharmacol; 2012 Oct; 74(4):685-90. PubMed ID: 22554404
[TBL] [Abstract][Full Text] [Related]
9. Pharmacovigilance-related topics at the level of the International Conference on Harmonisation (ICH).
Bahri P; Tsintis P
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):377-87. PubMed ID: 15517542
[TBL] [Abstract][Full Text] [Related]
10. Pharmacovigilance: methods, recent developments and future perspectives.
Härmark L; van Grootheest AC
Eur J Clin Pharmacol; 2008 Aug; 64(8):743-52. PubMed ID: 18523760
[TBL] [Abstract][Full Text] [Related]
11. [The new pharmacovigilance legislation in practice].
Broekmans AW; Mol PG
Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
[TBL] [Abstract][Full Text] [Related]
12. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria.
Shakir SA; Layton D
Drug Saf; 2002; 25(6):467-71. PubMed ID: 12071785
[TBL] [Abstract][Full Text] [Related]
13. Pharmacovigilance in perspective.
Meyboom RH; Egberts AC; Gribnau FW; Hekster YA
Drug Saf; 1999 Dec; 21(6):429-47. PubMed ID: 10612268
[TBL] [Abstract][Full Text] [Related]
14. European commission consultation on pharmacovigilance.
Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
[No Abstract] [Full Text] [Related]
15. Erice Statement 2009: communication, medicines and patient safety.
Br J Clin Pharmacol; 2010 Feb; 69(2):207-8. PubMed ID: 20233186
[No Abstract] [Full Text] [Related]
16. What do stakeholders think about pharmacovigilance?
Edwards IR; Graedon T
Drug Saf; 2010 Aug; 33(8):619-21. PubMed ID: 20635819
[No Abstract] [Full Text] [Related]
17. A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee.
Pacurariu AC; Coloma PM; van Haren A; Genov G; Sturkenboom MC; Straus SM
Drug Saf; 2014 Dec; 37(12):1059-66. PubMed ID: 25398646
[TBL] [Abstract][Full Text] [Related]
18. Post Launch Monitoring of food products: what can be learned from pharmacovigilance.
van Puijenbroek EP; Hepburn PA; Herd TM; van Grootheest AC
Regul Toxicol Pharmacol; 2007 Mar; 47(2):213-20. PubMed ID: 17204356
[TBL] [Abstract][Full Text] [Related]
19. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems.
Pal SN; Duncombe C; Falzon D; Olsson S
Drug Saf; 2013 Feb; 36(2):75-81. PubMed ID: 23329541
[TBL] [Abstract][Full Text] [Related]
20. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
